DBV Technologies (NASDAQ:DBVT) outlined its late-stage plans for VIASKIN Peanut and its broader epicutaneous immunotherapy platform during a presentation at the Citizens Life Sciences Conference, with ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic ...
On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear Accelerated ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...
In 2020, the FDA refused to approve DBV Technologies lead candidate, the Viaskin Peanut patch, citing adhesion issues. DBV enlarged the patch and had intended to try again without running a new phase ...
DBV announced that the FDA lifted a partial clinical hold on its phase 3 study of DBV712. The product is a patch intended for use in kids with peanut allergies. The FDA placed DBV Technologies' phase ...
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT - CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American ...
DBV Technologies has posted phase 3 data suggesting safety and compliance are unlikely to scuttle its hopes of winning approval of peanut allergy treatment Viaskin Peanut. Shares in DBV rose on the ...
Two of the leaders responsible for regulatory and product development at DBV Technologies are set to leave the company this month. The departures deprive DBV of senior members of its regulatory team ...
Hosted on MSN
DBV Technologies stock (DBVT) soars as clinical trial results trigger analyst price target increases
DBV Technologies (DBVT) stock underwent a massive rally on Wednesday after positive coverage from top analysts following a clinical trial update. Let’s dig into the updated DBVT stock coverage ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results